Editas Medicine, Inc.

Editas maintains meaningful upside potential tied to its CRISPR gene-editing pipeline, with several analysts issuing Buy ratings and price targets well above current levels — including Evercore ISI at $15 and Jones Trading at $8 — reflecting confidence that clinical milestones could significantly re-rate the stock.

Skeptics point to persistent revenue misses and deeply negative EPS expectations of -$1.03 for the current fiscal year, with firms such as Weiss Ratings and Wall Street Zen issuing Sell ratings, signaling doubt that the pipeline will translate into near-term commercial or clinical success.

A majority of the 13 covering analysts — 7 with Buy ratings — see substantial upside, with a consensus 12-month price target of $5.78, representing nearly 94% upside from current levels. Evercore ISI's $15 target suggests some analysts believe the market is deeply undervaluing Editas' long-term platform potential.

With the stock trading near $2.98, close to its 52-week low of $1.66, and some price targets as low as $1, a segment of analysts views the current valuation as still too generous given the company's lack of revenue traction and ongoing cash burn, reflecting a wide and unresolved disagreement on intrinsic value.

Technical indicators from mid-2025 showed buy signals from both short- and long-term moving averages, with price momentum suggesting a potential 114% rise over three months. Analysts at Chardan Capital raised their price target from $3.50 to $4.00, reflecting growing institutional interest in the stock's recovery trajectory.

Short interest surged to 23.69% of the public float as of June 30, 2026 — a 22% increase from the prior period — with a days-to-cover ratio of 7.2. Editas shares also fell below their 50-day moving average, and insider selling has added to concerns about near-term downside risk.